S 1041
Affordable Prescriptions for Patients Act
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed Senate
- Passed House
- To President
- Became Law
Bill overview
The Affordable Prescriptions for Patients Act modifies patent law to potentially lower the cost of biosimilar drugs. Specifically, it limits the number of patents a biologic drug manufacturer can use to challenge a biosimilar competitor – capping it at 20 patents, with 10 of those patents having been filed more than four years after the original drug’s approval. This change aims to streamline the approval process for biosimilars and encourage competition in the pharmaceutical market. The bill also allows courts to increase this limit under certain circumstances, such as when necessary for justice or due to significant changes in the biosimilar product.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.